Eli Lilly (LLY) has built up its inventory for its experimental weight loss pill, orforglipron, as the Indiana-based pharma giant awaits a potential FDA approval for the oral GLP-1 drug over the coming months, according to a regulatory filing.
With its 10-K filing on Thursday, the company recorded $1.5B as pre-launch inventories primarily related to orforglipron as of Dec. 31, 2025, compared to $548.1M a year ago.
In an interview with Reuters, Lilly’s (LLY) medical chief said in January that the company has enough supplies of orforglipron to meet the anticipated demand once the FDA approves the once-daily pill.
LLY has won a U.S. National Priority Voucher for orforglipron, which is currently on track for a potential U.S. regulatory nod in Q2 2026 as an oral treatment option for obese or overweight adults.
Rival Novo Nordisk (NVO) has already gained first-mover advantage in the market for oral weight loss drugs after the Danish drugmaker introduced its Wegovy pill for cash-paying U.S. customers at $149 per month last month.